View in EDS HTML Full Text PDF Full Text

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.

Saved in:
Bibliographic Details
Title: Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.
Authors: Koshino A; Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, the Netherlands.; Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan., Neuen BL; The George Institute for Global Health, UNSW Sydney, Sydney, Australia., Jongs N; Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, the Netherlands., Pollock C; Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Sydney, Australia.; Royal North Shore Hospital, St Leonards, NSW, Australia., Greasley PJ; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden., Andersson EM; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden., Hammarstedt A; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden., Karlsson C; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden., Langkilde AM; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden., Wada T; Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan., Heerspink HJL; Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, the Netherlands. h.j.lambers.heerspink@umcg.nl.; The George Institute for Global Health, UNSW Sydney, Sydney, Australia. h.j.lambers.heerspink@umcg.nl.
Source: Cardiovascular diabetology [Cardiovasc Diabetol] 2023 Nov 28; Vol. 22 (1), pp. 330. Date of Electronic Publication: 2023 Nov 28.
Publication Type: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38017482
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Koshino+A%22">Koshino A</searchLink>; Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, the Netherlands.; Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan.<br /><searchLink fieldCode="AU" term="%22Neuen+BL%22">Neuen BL</searchLink>; The George Institute for Global Health, UNSW Sydney, Sydney, Australia.<br /><searchLink fieldCode="AU" term="%22Jongs+N%22">Jongs N</searchLink>; Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Pollock+C%22">Pollock C</searchLink>; Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Sydney, Australia.; Royal North Shore Hospital, St Leonards, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Greasley+PJ%22">Greasley PJ</searchLink>; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Andersson+EM%22">Andersson EM</searchLink>; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Hammarstedt+A%22">Hammarstedt A</searchLink>; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Karlsson+C%22">Karlsson C</searchLink>; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Langkilde+AM%22">Langkilde AM</searchLink>; BioPharmaceuticals Research and Development, AstraZeneca, Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Wada+T%22">Wada T</searchLink>; Department of Nephrology and Laboratory Medicine, Kanazawa University, Ishikawa, Japan.<br /><searchLink fieldCode="AU" term="%22Heerspink+HJL%22">Heerspink HJL</searchLink>; Department of Clinical Pharmacy and Pharmacology, University of Groningen, Groningen, the Netherlands. h.j.lambers.heerspink@umcg.nl.; The George Institute for Global Health, UNSW Sydney, Sydney, Australia. h.j.lambers.heerspink@umcg.nl.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101147637%22">Cardiovascular diabetology</searchLink> [Cardiovasc Diabetol] 2023 Nov 28; Vol. 22 (1), pp. 330. <i>Date of Electronic Publication: </i>2023 Nov 28.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BioMed+Central%22">BioMed Central </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101147637 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1475-2840 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214752840%22">14752840 </searchLink><i>NLM ISO Abbreviation: </i>Cardiovasc Diabetol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38017482
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1186/s12933-023-02027-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 330
    Titles:
      – TitleFull: Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Koshino A
      – PersonEntity:
          Name:
            NameFull: Neuen BL
      – PersonEntity:
          Name:
            NameFull: Jongs N
      – PersonEntity:
          Name:
            NameFull: Pollock C
      – PersonEntity:
          Name:
            NameFull: Greasley PJ
      – PersonEntity:
          Name:
            NameFull: Andersson EM
      – PersonEntity:
          Name:
            NameFull: Hammarstedt A
      – PersonEntity:
          Name:
            NameFull: Karlsson C
      – PersonEntity:
          Name:
            NameFull: Langkilde AM
      – PersonEntity:
          Name:
            NameFull: Wada T
      – PersonEntity:
          Name:
            NameFull: Heerspink HJL
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 28
              M: 11
              Text: 2023 Nov 28
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1475-2840
          Numbering:
            – Type: volume
              Value: 22
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Cardiovascular diabetology
              Type: main
ResultId 1